We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate
We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.
即使企业亏损,如果股东以合适的价格收购一家好的企业,他们也有可能赚钱。例如,生物技术和矿业勘探公司通常会亏损多年,然后才能通过新的处理方法或矿物发现获得成功。但严酷的现实是,许多亏损公司耗尽了所有现金并破产。
So, the natural question for Edgewise Therapeutics (NASDAQ:EWTX) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn.
因此,对于Edgewise Therapeutics(纳斯达克股票代码:EWTX)股东来说,自然而然的问题是他们是否应该担心其现金消耗率。在本报告中,我们将考虑公司的年度负自由现金流,此后将其称为 “现金消耗”。让我们首先检查一下企业的现金与其现金消耗的关系。
See our latest analysis for Edgewise Therapeutics
查看我们对 Edgewise Therapeutics 的最新分析
When Might Edgewise Therapeutics Run Out Of Money?
Edgewise Therapeutics 什么时候会没钱?
You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When Edgewise Therapeutics last reported its balance sheet in September 2023, it had zero debt and cash worth US$290m. Looking at the last year, the company burnt through US$86m. So it had a cash runway of about 3.4 years from September 2023. A runway of this length affords the company the time and space it needs to develop the business. Depicted below, you can see how its cash holdings have changed over time.
你可以通过将公司的现金金额除以现金的支出率来计算公司的现金流量。当Edgewise Therapeutics上次于2023年9月公布其资产负债表时,其负债为零,现金价值2.9亿美元。纵观去年,该公司耗资8600万美元。因此,从2023年9月起,它的现金流约为3.4年。如此长度的跑道为公司提供了发展业务所需的时间和空间。如下所示,您可以看到其现金持有量随着时间的推移而发生了怎样的变化。
![debt-equity-history-analysis](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231208/0-8056ca7bba564a09b12a8b22d54a9590-0-e445637d9af0f819b7077bc07638af4e.png/big)
How Is Edgewise Therapeutics' Cash Burn Changing Over Time?
随着时间的推移,Edgewise Therapeutics的现金消耗有何变化?
Edgewise Therapeutics didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. During the last twelve months, its cash burn actually ramped up 63%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.
去年,Edgewise Therapeutics没有录得任何收入,这表明它是一家处于早期阶段的公司,仍在发展业务。尽管如此,作为评估其现金消耗情况的一部分,我们仍然可以研究其现金消耗轨迹。在过去的十二个月中,其现金消耗实际上增加了63%。通常,现金消耗的增加只是意味着公司正在加速其业务发展,但应始终注意,这会导致现金流萎缩。虽然过去总是值得研究的,但最重要的是未来。因此,你可能想看看该公司在未来几年预计将增长多少。
How Easily Can Edgewise Therapeutics Raise Cash?
Edgewise Therapeutics 能轻松筹集资金吗?
While Edgewise Therapeutics does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.
尽管Edgewise Therapeutics确实有稳健的现金流,但其现金消耗轨迹可能会让一些股东考虑公司何时可能需要筹集更多资金。一般而言,上市企业可以通过发行股票或承担债务来筹集新现金。通常,企业会自行出售新股以筹集现金和推动增长。通过观察公司相对于其市值的现金消耗,我们可以深入了解如果公司需要筹集足够的现金来弥补下一年的现金消耗,股东会被稀释多少。
Edgewise Therapeutics' cash burn of US$86m is about 20% of its US$428m market capitalisation. That's not insignificant, and if the company had to sell enough shares to fund another year's growth at the current share price, you'd likely witness fairly costly dilution.
Edgewise Therapeutics的8600万美元现金消耗约为其4.28亿美元市值的20%。这并非微不足道,如果公司必须以当前股价出售足够的股票来为下一年的增长提供资金,那么您可能会看到相当昂贵的稀释。
So, Should We Worry About Edgewise Therapeutics' Cash Burn?
那么,我们应该担心 Edgewise Therapeutics 的现金消耗吗?
On this analysis of Edgewise Therapeutics' cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. Considering all the factors discussed in this article, we're not overly concerned about the company's cash burn, although we do think shareholders should keep an eye on how it develops. Taking a deeper dive, we've spotted 3 warning signs for Edgewise Therapeutics you should be aware of, and 2 of them are potentially serious.
根据对Edgewise Therapeutics现金消耗的分析,我们认为其现金流道令人放心,而其不断增加的现金消耗让我们有些担忧。考虑到本文中讨论的所有因素,尽管我们确实认为股东应该密切关注公司的发展情况,但我们并不过分担心公司的现金消耗。更深入地讲,我们发现了你应该注意的 Edgewise Therapeutics 的 3 个警告信号,其中 2 个可能很严重。
Of course Edgewise Therapeutics may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.
当然,Edgewise Therapeutics可能不是最好的买入股票。因此,你可能希望看到这份免费收藏的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。